Annelie Bergman1, Abdul Rashid Qureshi1, Mathias Haarhaus1, Bengt Lindholm1, Peter Barany1, Olof Heimburger1, Peter Stenvinkel1, Björn Anderstam2. 1. Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Hospital Huddinge, Karolinska University, KFC, Novum, 141 86, Stockholm, Sweden. 2. Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Hospital Huddinge, Karolinska University, KFC, Novum, 141 86, Stockholm, Sweden. bjorn.anderstam@ki.se.
Abstract
BACKGROUND: Alkaline phosphatase (ALP) and bone-specific ALP (BALP) are implicated in the abnormal skeletal mineralization and accelerated vascular calcification in chronic kidney disease (CKD) patients. Whereas ALP and BALP may predict mortality in CKD, BALP is reported to have higher sensitivity and specificity than total ALP in reflecting histological alterations in bone; however, results on their associations with bone mineral density (BMD) are inconsistent. Here we evaluated associations of total ALP and BALP with BMD during up to 24 months in end-stage renal disease (ESRD) patients. METHODS: In this longitudinal study, 194 ESRD patients (median age 57 years, 66 % male, 32 % diabetes mellitus, mean body mass index 24.8 kg/m2) underwent measurements of total ALP and BALP and total and regional body BMD (by dual-energy X-ray absorptiometry) at dialysis initiation (n = 194), and after 12 (n = 98) and 24 months (n = 40) on dialysis. RESULTS: At baseline, patients had median total ALP 65.4 (43.3-126.4) U/l, BALP 13.5 (7.1-27.3) µg/l and BMD 1.14 (0.97-1.31) g/cm2. During the study period, serum concentrations of ALP and BALP increased significantly (p < 0.001), whereas total and regional BMD remained stable. BMD correlated inversely with total ALP (rho = -0.20, p = 0.005) and BALP (rho = -0.30, p < 0.001) at baseline, and correlations were similar also at 12 and 24 months. CONCLUSION: ALP and BALP are equally accurate albeit weak predictors of BMD in ESRD patients, both at baseline and longitudinally. The dissociation between stable BMD and increasing ALP and BALP may possibly reflect increased soft tissue calcifications with time on dialysis.
BACKGROUND:Alkaline phosphatase (ALP) and bone-specific ALP (BALP) are implicated in the abnormal skeletal mineralization and accelerated vascular calcification in chronic kidney disease (CKD) patients. Whereas ALP and BALP may predict mortality in CKD, BALP is reported to have higher sensitivity and specificity than total ALP in reflecting histological alterations in bone; however, results on their associations with bone mineral density (BMD) are inconsistent. Here we evaluated associations of total ALP and BALP with BMD during up to 24 months in end-stage renal disease (ESRD) patients. METHODS: In this longitudinal study, 194 ESRDpatients (median age 57 years, 66 % male, 32 % diabetes mellitus, mean body mass index 24.8 kg/m2) underwent measurements of total ALP and BALP and total and regional body BMD (by dual-energy X-ray absorptiometry) at dialysis initiation (n = 194), and after 12 (n = 98) and 24 months (n = 40) on dialysis. RESULTS: At baseline, patients had median total ALP 65.4 (43.3-126.4) U/l, BALP 13.5 (7.1-27.3) µg/l and BMD 1.14 (0.97-1.31) g/cm2. During the study period, serum concentrations of ALP and BALP increased significantly (p < 0.001), whereas total and regional BMD remained stable. BMD correlated inversely with total ALP (rho = -0.20, p = 0.005) and BALP (rho = -0.30, p < 0.001) at baseline, and correlations were similar also at 12 and 24 months. CONCLUSION:ALP and BALP are equally accurate albeit weak predictors of BMD in ESRDpatients, both at baseline and longitudinally. The dissociation between stable BMD and increasing ALP and BALP may possibly reflect increased soft tissue calcifications with time on dialysis.
Entities:
Keywords:
Alkaline phosphatase; Bone mineral density; Bone-specific alkaline phosphatase; Cardiovascular disease; Chronic kidney disease
Authors: Deborah L Regidor; Csaba P Kovesdy; Rajnish Mehrotra; Mehdi Rambod; Jennie Jing; Charles J McAllister; David Van Wyck; Joel D Kopple; Kamyar Kalantar-Zadeh Journal: J Am Soc Nephrol Date: 2008-07-30 Impact factor: 10.121
Authors: An R J Bervoets; Goce B Spasovski; Geert J Behets; Geert Dams; Momir H Polenakovic; Katica Zafirovska; Viviane O Van Hoof; Marc E De Broe; Patrick C D'Haese Journal: Am J Kidney Dis Date: 2003-05 Impact factor: 8.860
Authors: Keisuke Matsubara; Mohamed E Suliman; Abdul Rashid Qureshi; Jonas Axelsson; Leena Martola; Olof Heimbürger; Peter Barany; Peter Stenvinkel; Bengt Lindholm Journal: Blood Purif Date: 2008-04-18 Impact factor: 2.614
Authors: Maria Fusaro; Maurizio Gallieni; Andrea Aghi; Maria Antonietta Rizzo; Giorgio Iervasi; Thomas L Nickolas; Fabrizio Fabris; Maria Cristina Mereu; Sandro Giannini; Stefania Sella; Andrea Giusti; Annalisa Pitino; Graziella D'Arrigo; Maurizio Rossini; Davide Gatti; Maura Ravera; Luca Di Lullo; Antonio Bellasi; Giuliano Brunori; Antonio Piccoli; Giovanni Tripepi; Mario Plebani Journal: J Nephrol Date: 2019-02-13 Impact factor: 3.902
Authors: Fellype de Carvalho Barreto; Cleber Rafael Vieira da Costa; Luciene Machado Dos Reis; Melani Ribeiro Custódio Journal: J Bras Nefrol Date: 2018-11-29